ChemicalBook > CAS DataBase List > AFN-1252

AFN-1252

Product Name
AFN-1252
CAS No.
620175-39-5
Chemical Name
AFN-1252
Synonyms
CS-2098;AFN-1252;Debio-1452;AFN-1252, API-1252;Debio-1452(AFN1252);AFN-1252(Debio 1452);AFN-1252, 10 mM in DMSO;API1252; DEBIO1452;API 1252; DEBIO-1452;API1252; DEBIO1452;Antibiotic,AFN 1252,AFN1252,inhibit,API1252,Bacterial,Debio-1452,AFN-1252,Debio1452,Inhibitor,API 1252;(E)-N-Methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
CBNumber
CB23041381
Molecular Formula
C22H21N3O3
Formula Weight
375.42
MOL File
620175-39-5.mol
More
Less

AFN-1252 Property

Boiling point:
601.2±65.0 °C(Predicted)
Density 
1.28±0.1 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
DMSO:5.8(Max Conc. mg/mL);15.45(Max Conc. mM)
form 
A crystalline solid
pka
3.60±0.20(Predicted)
color 
White to off-white
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
24686
Product name
AFN-1252
Purity
≥98%
Packaging
1mg
Price
$62
Updated
2024/03/01
Cayman Chemical
Product number
24686
Product name
AFN-1252
Purity
≥98%
Packaging
5mg
Price
$270
Updated
2024/03/01
Cayman Chemical
Product number
24686
Product name
AFN-1252
Purity
≥98%
Packaging
10mg
Price
$507
Updated
2024/03/01
Cayman Chemical
Product number
24686
Product name
AFN-1252
Purity
≥98%
Packaging
25mg
Price
$1189
Updated
2024/03/01
TRC
Product number
A425005
Product name
AFN-1252
Packaging
5mg
Price
$285
Updated
2021/12/16
More
Less

AFN-1252 Chemical Properties,Usage,Production

Description

AFN-1252 is an inhibitor of staphylococcal enoyl-acyl carrier protein reductase (FabI; Ki = 12.8 nM), an enzyme that activates bacterial fatty acid biosynthesis. It is selective for isolates of methicillin-susceptible and methicillin-resistant S. aureus (MIC90s = ≤0.008 μg/ml) over isolates of S. pneumoniae, β-hemolytic streptococci, Enterococcus, Enterobacteriaceae, non-fermentative Gram-negative bacilli, and M. catarrhalis (MIC90s = >4 μg/ml). In vivo, AFN-1252 increases survival in a murine acute lethal septicemia model, showing 100% survival when administered at a single oral dose of 1 mg/kg.

Uses

AFN-1252 is a staphylococcus-selective enoyl-acyl carrier protein reductase (FabI) inhibitor. An antimicrobial agent

Enzyme inhibitor

This selective, orally available, first-in-class antibiotic (FW = 375.43 g/mol; CAS 620175-39-5; Formulated in 1% Poloxamer 407) is a potent inhibitor of Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI), thereby preventing fatty acyl chain elongation and disrupting biosynthesis of both saturated and unsaturated fatty acids needed for bacterial growth. It demonstrates exceptional potency and specificity against staphylococcal isolates, with typical S. aureus MIC ranges of 0.002–0.12 μg/mL and MIC90s of ≤ 0.015 μg/mL. Mode of Action: FabI is the only enoyl-ACP reductase in S. aureus, S. epidermidis, and related staphylococci, with no alternative enzyme or rescue pathway, including processing of exogenously supplied fatty acids. Such metabolic features suggest FabI may be essential to cell viability in Staphylococcus spp. The inhibitor’s target was convincingly confirmed (a) by using direct enzyme assays (IC50 = 14 nM, with no inhibition of the human enzyme, even at 67 μM); (b) by employing radiolabeled acetate to demonstrate that AFN-1252 greatly reduced incorporation into lipids; (c) by co-crystallizing AFN-1252 and FabI in the presence of the unnatural substrate 3′-NADPH, and (d) by genetically determining AFN-1252’s spontaneous resistance frequency and characterizing AFN-1252-resistant FabI mutants. In socalled time-kill assays, AFN-1252 caused a time-dependent reduction in the viability of S. aureus ATCC 29213 (MSSA) and S. aureus ATCC 43300 (MRSA), with similar magnitudes and rates of killing were obtained at 4 and 128 times the MIC (i.e., 2.0- and 2.9-log10 reductions).

AFN-1252 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

AFN-1252 Suppliers

MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
Musechem
Tel
+1-800-259-7612
Fax
+1-800-259-7612
Email
info@musechem.com
Country
United States
ProdList
4660
Advantage
60
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Cckinase, Inc.
Tel
+1 (732)236-3202
Email
sales@cckinase.com
Country
United States
ProdList
2738
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
52924
Advantage
58
TargetMol Chemicals Inc.
Tel
Email
support@targetmol.com
Country
United States
ProdList
38631
Advantage
58
BOC Sciences
Tel
16314854226
Email
info@bocsci.com
Country
United States
ProdList
9923
Advantage
65
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58

620175-39-5, AFN-1252Related Search:


  • AFN-1252
  • (E)-3-(1,2,3,4-tetrahydro-2-oxo-1,8-naphthyridin-6-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide
  • (2E)-N-Methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
  • Debio-1452
  • (E)-N-Methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
  • AFN-1252, API-1252
  • CS-2098
  • AFN-1252(Debio 1452)
  • API1252; DEBIO1452;API 1252; DEBIO-1452;API1252; DEBIO1452
  • 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)-
  • Debio-1452(AFN1252)
  • Antibiotic,AFN 1252,AFN1252,inhibit,API1252,Bacterial,Debio-1452,AFN-1252,Debio1452,Inhibitor,API 1252
  • AFN-1252, 10 mM in DMSO
  • 620175-39-5